On April 14, 2023, Mind Medicine (MindMed) Inc. announced positive topline data from a double-blind, investigator-initiated trial evaluating lysergide in the treatment of Major Depressive Disorder at the University Hospital Basel (UHB) and the University Hospital of Psychiatry. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.